Osimertinib, also known as Tagrisso, is a revolutionary targeted therapy for cancer patients, specifically those with non-small cell lung cancer (NSCLC). This medication works by inhibiting the tyrosine kinase activity of the EGFR (epidermal growth factor receptor) and c-Met proteins, which are known to promote the growth and spread of cancer cells. Osimertinib has gained significant attention...